189 related articles for article (PubMed ID: 24223115)
1. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease.
Hashiba M; Ono M; Hyogo H; Ikeda Y; Masuda K; Yoshioka R; Ishikawa Y; Nagata Y; Munekage K; Ochi T; Hirose A; Nozaki-Fujimura Y; Noguchi S; Okamoto N; Chayama K; Suganuma N; Saibara T
PLoS One; 2013; 8(11):e76161. PubMed ID: 24223115
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of postprandial hypoglycemia in patients with nonalcoholic fatty liver disease by oral glucose tolerance testing and continuous glucose monitoring.
Oki Y; Ono M; Hyogo H; Ochi T; Munekage K; Nozaki Y; Hirose A; Masuda K; Mizuta H; Okamoto N; Saibara T
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):797-805. PubMed ID: 29634665
[TBL] [Abstract][Full Text] [Related]
3. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
4. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis.
Molloy JW; Calcagno CJ; Williams CD; Jones FJ; Torres DM; Harrison SA
Hepatology; 2012 Feb; 55(2):429-36. PubMed ID: 21987293
[TBL] [Abstract][Full Text] [Related]
5. Glycemic Control Is Associated with Histological Findings of Nonalcoholic Fatty Liver Disease.
Miyake T; Furukawa S; Matsuura B; Yoshida O; Miyazaki M; Shiomi A; Kanamoto A; Nakaguchi H; Nakamura Y; Imai Y; Koizumi M; Watanabe T; Yamamoto Y; Koizumi Y; Tokumoto Y; Hirooka M; Kumagi T; Takesita E; Ikeda Y; Abe M; Hiasa Y
Diabetes Metab J; 2024 May; 48(3):440-448. PubMed ID: 38310878
[TBL] [Abstract][Full Text] [Related]
6. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
Alexopoulos AS; Crowley MJ; Wang Y; Moylan CA; Guy CD; Henao R; Piercy DL; Seymour KA; Sudan R; Portenier DD; Diehl AM; Coviello AD; Abdelmalek MF
Hepatology; 2021 Sep; 74(3):1220-1233. PubMed ID: 33724511
[TBL] [Abstract][Full Text] [Related]
7. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
Haukeland JW; Konopski Z; Linnestad P; Azimy S; Marit Løberg E; Haaland T; Birkeland K; Bjøro K
Scand J Gastroenterol; 2005 Dec; 40(12):1469-77. PubMed ID: 16293559
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD.
Coccia F; Testa M; Guarisco G; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):106-113. PubMed ID: 31677889
[TBL] [Abstract][Full Text] [Related]
9. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.
Kowdley KV; Belt P; Wilson LA; Yeh MM; Neuschwander-Tetri BA; Chalasani N; Sanyal AJ; Nelson JE;
Hepatology; 2012 Jan; 55(1):77-85. PubMed ID: 21953442
[TBL] [Abstract][Full Text] [Related]
10. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
[TBL] [Abstract][Full Text] [Related]
11. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease.
Fujii H; Imajo K; Yoneda M; Nakahara T; Hyogo H; Takahashi H; Hara T; Tanaka S; Sumida Y; Eguchi Y; Chayama K; Nakajima A; Nishimoto N; Kawada N;
J Gastroenterol Hepatol; 2019 Aug; 34(8):1390-1395. PubMed ID: 30600551
[TBL] [Abstract][Full Text] [Related]
12. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.
Charlton M; Angulo P; Chalasani N; Merriman R; Viker K; Charatcharoenwitthaya P; Sanderson S; Gawrieh S; Krishnan A; Lindor K
Hepatology; 2008 Feb; 47(2):484-92. PubMed ID: 18220286
[TBL] [Abstract][Full Text] [Related]
13. Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone.
Chai SY; Pan XY; Song KX; Huang YY; Li F; Cheng XY; Qu S
Lipids Health Dis; 2014 Jan; 13():7. PubMed ID: 24397589
[TBL] [Abstract][Full Text] [Related]
14. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?
Cengiz M; Candır BA; Yılmaz G; Akyol G; Ozenirler S
World J Gastroenterol; 2013 Nov; 19(42):7412-8. PubMed ID: 24259972
[TBL] [Abstract][Full Text] [Related]
15. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
16. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.
Bril F; Lomonaco R; Orsak B; Ortiz-Lopez C; Webb A; Tio F; Hecht J; Cusi K
Hepatology; 2014 Jun; 59(6):2178-87. PubMed ID: 24777953
[TBL] [Abstract][Full Text] [Related]
17. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease.
Zein CO; Unalp A; Colvin R; Liu YC; McCullough AJ;
J Hepatol; 2011 Apr; 54(4):753-9. PubMed ID: 21126792
[TBL] [Abstract][Full Text] [Related]
18. Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD.
Mahmoud AA; Bakir AS; Shabana SS
Saudi J Gastroenterol; 2012; 18(5):327-33. PubMed ID: 23006461
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
20. Hematocrit is associated with fibrosis in patients with nonalcoholic steatohepatitis.
Li Y; Liu L; Wang B; Wang J; Chen D
Eur J Gastroenterol Hepatol; 2014 Mar; 26(3):332-8. PubMed ID: 24172912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
